Loading clinical trials...
Loading clinical trials...
A Three Part, Staggered Cohort, Open-label and Double Blind, Randomized, Placebo Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of Eltrombopag, a Thrombopoietin Receptor Agonist, in Previously Treated Pediatric Patients With Chronic ITP.
Conditions
Interventions
eltrombopag
Placebo
Locations
33
United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Orange, California, United States
GSK Investigational Site
Jacksonville, Florida, United States
GSK Investigational Site
Orlando, Florida, United States
GSK Investigational Site
Orlando, Florida, United States
GSK Investigational Site
Chicago, Illinois, United States
Start Date
September 30, 2009
Primary Completion Date
February 1, 2014
Completion Date
February 1, 2014
Last Updated
October 12, 2018
NCT01072162
NCT00442871
NCT01064336
NCT01098487
NCT00424177
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions